Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma

  • Technology appraisal guidance
  • TA414
  • Published: 

History

Expected publication

Final appraisal determination

Draft guidance

Melanoma (BRAF V600, advanced, unresectable, metastatic) - cobimetinib (with vemurafenib): final scope (post referral)

Melanoma (BRAF V600, advanced, unresectable, metastatic) - cobimetinib (with vemurafenib): final matrix (post referral)

Melanoma (BRAF V600, advanced, unresectable, metastatic) - cobimetinib (with vemurafenib): NICE response to scope and matrix (post referral)

Melanoma (BRAF V600, advanced, unresectable, metastatic) - cobimetinib (with vemurafenib): equality impact assessment (post referral)

Melanoma (BRAF V600, advanced, unresectable, metastatic) - cobimetinib (with vemurafenib): draft scope for consultation (pre-referral) - January 2015

Melanoma (BRAF V600, advanced, unresectable, metastatic) - cobimetinib (with vemurafenib): provisional matrix (pre-referral) - January 2015